Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide–Dependent Mechanism
Open accessThe DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) increases tissue glucose uptake and causes vasodilation independent of insulin. We examined the effect of GLP-1 on muscle microvasculature and glucose uptake. After confirming that GLP-1 potently stimulates nitric oxide (NO) synthase (NOS) phosphorylation in endothelial cells, overnight-fasted adult male rats received continuous GLP-1 infusion (30 pmol/kg/min) for 2 h plus or minus NOS inhibition. Muscle microvascular blood volume (MBV), microvascular blood flow velocity (MFV), and microvascular blood flow (MBF) were determined. Additional rats received GLP-1 or saline for 30 min and muscle insulin clearance/uptake was determined. GLP-1 infusion acutely increased muscle MBV (P < 0.04) within 30 min without altering MFV or femoral blood flow. This effect persisted throughout the 120-min infusion period, leading to a greater than twofold increase in muscle MBF (P < 0.02). These changes were paralleled with increases in plasma NO levels, muscle interstitial oxygen saturation, hind leg glucose extraction, and muscle insulin clearance/uptake. NOS inhibition blocked GLP-1–mediated increases in muscle MBV, glucose disposal, NO production, and muscle insulin clearance/uptake. In conclusion, GLP-1 acutely recruits microvasculature and increases basal glucose uptake in muscle via a NO-dependent mechanism. Thus, GLP-1 may afford potential to improve muscle insulin action by expanding microvascular endothelial surface area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 can also enhance the uptake and utilization of glucose in muscle and adipose tissues.207–209”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [207]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183 · cited 3×
“Incubation of the cells with exendin (9-39) (10 nmol/L), a specific GLP-1 receptor antagonist, completely abolished GLP-1–induced eNOS phosphorylation at Ser(1177), confirming that GLP-1 acted via its receptors (Fig.”
BackgroundRetractedThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 5×
“GLP-1 was given as continuous infusion because of its shorter plasma half-life secondary to rapid degradation by enzyme dipeptidyl peptidase IV (5,31).”
BackgroundMethodInfluentialThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 2×
“Activation of the GLP-1 receptors regulates blood glucose concentration by mechanisms including enhanced insulin synthesis/secretion, suppressed glucagon secretion, slowed gastric emptying, and enhanced satiety (5).”
BackgroundMethodKim, J.-A., Montagnani, M., Koh, K. K., & Quon, M. J. (2006) · Circulation · doi:10.1161/circulationaha.105.563213 · Cited by 1,652
Adipose Tissue Hypoxia in Obesity and Its Impact on Adipocytokine Dysregulation
Hosogai, N., Fukuhara, A., Oshima, K., Miyata, Y., Tanaka, S., Segawa, K., Furukawa, S., Tochino, Y., Komuro, R., Matsuda, M., et al. (2007) · Diabetes · doi:10.2337/db06-0911 · Cited by 1,257
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Ye, J., Gao, Z., Yin, J., & He, Q. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00435.2007 · Cited by 840 · cited 2×
“Incubation of the cells with exendin (9-39) (10 nmol/L), a specific GLP-1 receptor antagonist, completely abolished GLP-1–induced eNOS phosphorylation at Ser(1177), confirming that GLP-1 acted via its receptors (Fig.”
BackgroundNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · cited 6×
“1): In protocol 1, rats received an intravenous infusion of saline (control) or GLP-1 (7-36) amide (30 pmol/kg/min; Bachem Americas, Inc.”
BackgroundMethodInfluentialEmerging role of adipose tissue hypoxia in obesity and insulin resistance
Ye, J. (2009) · International Journal of Obesity · doi:10.1038/ijo.2008.229 · Cited by 543
Cited by
Short-chain fatty acids in control of body weight and insulin sensitivity
Canfora, E. E., Jocken, J. W., & Blaak, E. E. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.128 · Cited by 2,298
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Diabetic Microvascular Disease: An Endocrine Society Scientific Statement
Barrett, E. J., Liu, Z., Khamaisi, M., King, G. L., Klein, R., Klein, B. E. K., Hughes, T. M., Craft, S., Freedman, B. I., Bowden, D. W., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01922 · Cited by 515
“In skeletal muscle, insulin and GLP-1 recruit muscle 1773 microvasculature via a NO-dependent mechanism (457,459-461), while exercise-induced muscle 1774 microvascular recruitment is largely NO-independent (462).”
BackgroundSelf-citationKim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514
Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic Disease
Horton, W. B., & Barrett, E. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa025 · Cited by 424
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
“Preclinical Studies A vascular target for GLP-1 action in the heart is consistent with studies demonstrating GLP-1–mediated increases in microvascular and coronary blood flow.(18,37,38) Sprague–Dawley rats infused with GLP-1 (30 pmol/kg per minute) exhibited significant increases in both microvascular blood volume and…”
BackgroundHealth effects of resistant starch
Lockyer, S., & Nugent, A. P. (2017) · Nutrition Bulletin · doi:10.1111/nbu.12244 · Cited by 312
“Such insulin-independent effects include muscle glucose uptake (Ayala et al. 2009), increased nitric oxide levels altering microvascular recruitment (Chai et al. 2012) and endothelial function (Nystrom et al. 2004).”
Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences
Stehouwer, C. D. A. (2018) · Diabetes · doi:10.2337/dbi17-0044 · Cited by 306
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“effect is believed to occur as a result of GLP-1 binding to the abundantly expressed, endothelial cell GLP-1R, triggering a downstream signaling cascade resulting in microvasculature recruitment via a NO-dependent mechanism (129, 131, 132).”
BackgroundGut microbiota and metabolic syndrome
Wang, P.-X., Deng, X.-R., Zhang, C.-H., & Yuan, H.-J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000696 · Cited by 246
Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
“These effects were significantly blocked by the GLP-1 antagonist, exendin (9-39)(120).”
BackgroundInfluentialBeyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
“In contrast, systemic delivery of native GLP1 acutely enhanced muscle microvascular blood flow in rats and humans; however, indirect contributions from hormones such as insulin or bioactive GLP1 degradation products cannot be excluded 29,33,34 .”
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Yabut, J. M., & Drucker, D. J. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 175
“There is little evidence that GLP-1 directly modulates muscle glucose uptake as GLP-1Rs are not expressed in skeletal muscle cells (9); however, infusion of native GLP-1 augments muscle microvascular blood flow in rats and healthy humans (108, 109).”
Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond
Cho, Y. M., Fujita, Y., & Kieffer, T. J. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170315 · Cited by 174
“In overnight-fasted rats, GLP-1 infusion increased hind leg glucose extraction, accompanied by increased plasma nitric oxide levels and muscle blood flow (133).”
BackgroundKoska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174
van Deuren, T., Blaak, E. E., & Canfora, E. E. (2022) · Obesity Reviews · doi:10.1111/obr.13498 · Cited by 180
Efficacy of increased resistant starch consumption in human type 2 diabetes
Bodinham, C. L., Smith, L., Thomas, E. L., Bell, J. D., Swann, J. R., Costabile, A., Russell-Jones, D., Umpleby, A. M., & Robertson, M. D. (2014) · Endocrine Connections · doi:10.1530/ec-14-0036 · Cited by 137
“GLP1 acutely raises nitric oxide (NO) levels and so acute changes in both microvascular recruitment (27) and endothelial function (28) at the level of the muscle are believed to be involved in this effect.”
Ussher, J. R., Baggio, L. L., Campbell, J. E., Mulvihill, E. E., Kim, M., Kabir, M. G., Cao, X., Baranek, B. M., Stoffers, D. A., Seeley, R. J., et al. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.04.009 · Cited by 139
Wei, R., Ma, S., Wang, C., Ke, J., Yang, J., Li, W., Liu, Y., Hou, W., Feng, X., Wang, G., et al. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00400.2015 · Cited by 137
Perna, S., Guido, D., Bologna, C., Solerte, S. B., Guerriero, F., Isu, A., & Rondanelli, M. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-015-0525-y · Cited by 125
“In rat skeletal muscle, GLP-1 enhances the insulin/ glucose extraction and oxygen delivery to the muscle tissues, through endothelial-derived vasodilator and nitric oxide mechanism and improving insulin resistance condition [11].”
BackgroundNew insights into insulin action and resistance in the vasculature
Manrique, C. M., Lastra, G., & Sowers, J. R. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12395 · Cited by 132
Oral Drugs Related with Muscle Wasting and Sarcopenia. A Review
Campins, L., Camps, M. V., Riera, A., Pleguezuelos, E., Yébenes, J. C., & Serra‐Prat, M. (2016) · Pharmacology · doi:10.1159/000448247 · Cited by 130
Insulin resistance in the vasculature
Mather, K. J., Steinberg, H. O., & Baron, A. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67166 · Cited by 120
“Most recently, studies with glucagon-like peptide 1 (GLP-1) have shown that it can act similarly to insulin as a microvascular vasodilator in skeletal muscle (10).”
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
Aroor, A. R., Sowers, J. R., Jia, G., & DeMarco, V. G. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00209.2014 · Cited by 111
Diabetes pharmacotherapy and effects on the musculoskeletal system
Kalaitzoglou, E., Fowlkes, J. L., Popescu, I., & Thrailkill, K. M. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3100 · Cited by 100
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
Glucagon-like peptide-1 receptor action in the vasculature
Almutairi, M., Al Batran, R., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2018.09.002 · Cited by 99
Subaran, S. C., Sauder, M. A., Chai, W., Jahn, L. A., Fowler, D. E., Aylor, K. W., Basu, A., & Liu, Z. (2014) · Clinical Science · doi:10.1042/cs20130708 · Cited by 95
Self-citationHausenloy, D. J., Whittington, H. J., Wynne, A. M., Begum, S. S., Theodorou, L., Riksen, N. P., Mocanu, M. M., & Yellon, D. M. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-154 · Cited by 102
Perspectives in GLP-1 Research: New Targets, New Receptors
Cantini, G., Mannucci, E., & Luconi, M. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.03.017 · Cited by 102
de Sire, R., Rizzatti, G., Ingravalle, F., Pizzoferrato, M., Petito, V., Lopetuso, L. R., Graziani, C., Alessandro de, S. I. R. E., Mentella, M. C., Mele, M. C., et al. (2018) · Minerva Gastroenterologica e Dietologica · doi:10.23736/s1121-421x.18.02511-4 · Cited by 101
Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives
Jin, T., & Weng, J. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00069.2016 · Cited by 83
Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes
YANG, J., REN, J., SONG, J., LIU, F., WU, C., WANG, X., GONG, L., LI, W., XIAO, F., YAN, F., et al. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1350 · Cited by 84
Green, C. J., Henriksen, T. I., Pedersen, B. K., & Solomon, T. P. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044284 · Cited by 80
“rats that GLP-1 increases glucose use and microvasculature in muscle [6] and that this is attenuated by the GLP-1 antagonist exendin-9.”
BackgroundMuscle Atrophy: Present and Future
Cao, R. Y., Li, J., Dai, Q., Li, Q. X., & Yang, J. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1435-3_29 · Cited by 83
Jokura, H., Watanabe, I., Umeda, M., Hase, T., & Shimotoyodome, A. (2015) · Nutrition Research · doi:10.1016/j.nutres.2015.07.005 · Cited by 80
Dong, Z., Chai, W., Wang, W., Zhao, L., Fu, Z., Cao, W., & Liu, Z. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00473.2012 · Cited by 71
Self-citationWang, N., Tan, A. W. K., Jahn, L. A., Hartline, L., Patrie, J. T., Lin, S., Barrett, E. J., Aylor, K. W., & Liu, Z. (2020) · Diabetes Care · doi:10.2337/dc19-1465 · Cited by 73
“Indeed, we have previously observed in rats that GLP-1 infusion can acutely increase muscle microvascular perfusion along with muscle interstitial oxygenation in both insulin-sensitive and insulin-resistant rodents (6,7).”
BackgroundSelf-citationPeng, W., Zhou, R., Sun, Z.-F., Long, J.-W., & Gong, Y.-Q. (2022) · Aging and disease · doi:10.14336/ad.2021.0928 · Cited by 71
“muscle via a NO-dependent mechanism [129]”
BackgroundXie, C., Qi, C., Zhang, J., Wang, W., Meng, X., Aikepaer, A., Lin, Y., Su, C., Liu, Y., Feng, X., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116791 · Cited by 76
Self-citationChai, W., Zhang, X., Barrett, E. J., & Liu, Z. (2014) · Diabetes · doi:10.2337/db13-1597 · Cited by 73
“Evidence thus far confirms that both insulin and GLP-1 recruit muscle microvasculature via an NO-dependent mechanism, as each is able to stimulate eNOS phosphorylation and NO production in vitro in cultured endothelial cells and increase plasma NO levels in vivo, and inhibition of eNOS activity completely abolishes in…”
BackgroundMethodInfluentialSelf-citationVascular function, insulin action, and exercise: an intricate interplay
Zheng, C., & Liu, Z. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.02.002 · Cited by 71
Self-citationHow glucagon-like peptide 1 receptor agonists work
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections · doi:10.1530/ec-21-0130 · Cited by 71
“The figure illustrates GLP-1(7-36) amide.”
Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation
Hviid, A. V. R., & Sørensen, C. M. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00280.2019 · Cited by 69
GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle
Sjøberg, K. A., Holst, J. J., Rattigan, S., Richter, E. A., & Kiens, B. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00283.2013 · Cited by 69
“(4) showed in the rat that GLP-1 acts via a NO-dependent mechanism similar to that utilized by insulin (37) and that the GLP-1-induced increase in MVR could be blunted by a preinfusion of the NO inhibitor L-NAME (4).”
BackgroundMethodResultInfluentialKihira, Y., Miyake, M., Hirata, M., Hoshina, Y., Kato, K., Shirakawa, H., Sakaue, H., Yamano, N., Izawa-Ishizawa, Y., Ishizawa, K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093856 · Cited by 66
“Moreover, GLP-1 amplifies insulin-mediated glucose uptake in adipocytes [35] and acutely increases microvascular recruitment and basal glucose uptake in muscle [36].”
BackgroundFeeding critically ill patients the right ‘whey’: thinking outside of the box. A personal view
Marik, P. E. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0051-2 · Cited by 66
“It should be noted that GLP-1 results in skeletal muscle microvascular recruitment with increased blood flow [81, 82] and nutrient delivery and this may play a role in the coordinated postprandial”
BackgroundVascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 65
Muscle microvasculature's structural and functional specializations facilitate muscle metabolism
Kusters, Y. H. A. M., & Barrett, E. J. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00443.2015 · Cited by 74
Oh, D. Y., & Walenta, E. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00115 · Cited by 75
Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials
Coppolino, G., Leporini, C., Rivoli, L., Ursini, F., Paola, E. D. D., Cernaro, V., Arturi, F., Bolignano, D., Russo, E., Sarro, G. D., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.001 · Cited by 64
“These effects respectively translated into increased microvascular blood flow and improved endothelial dysfunction in preclinical models [56,58].”
Nausheen, S., Shah, I. H., Pezeshki, A., Sigalet, D. L., & Chelikani, P. K. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00130.2013 · Cited by 67
“Consistent with other studies on GLP-1-induced glucose uptake in muscle (4, 11, 26), our findings suggest that GLP-1 may signal through PKA and AMPK to increase glucose uptake via the insulin-sensitive GLUT4 in muscle and fat.”
ResultShao, W., Wang, Z., Ip, W., Chiang, Y.-T., Xiong, X., Chai, T., Xu, C., Wang, Q., & Jin, T. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00600.2012 · Cited by 58
The effect of liraglutide on endothelial function in patients with type 2 diabetes
Nandy, D., Johnson, C., Basu, R., Joyner, M., Brett, J., Svendsen, C. B., & Basu, A. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114547358 · Cited by 56
Sarcopenia – Endocrinological and Neurological Aspects
Stangl, M. K., Böcker, W., Chubanov, V., Ferrari, U., Fischereder, M., Gudermann, T. W., Hesse, E., Meinke, P., Reincke, M., Reisch, N., et al. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0672-1007 · Cited by 67
“In rat skeletal muscle, GLP-1 improves insulin sensitivity [36].”
Diabetes pathogenesis and management: the endothelium comes of age
Love, K. M., Barrett, E. J., Malin, S. K., Reusch, J. E. B., Regensteiner, J. G., & Liu, Z. (2021) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjab024 · Cited by 57
“We have shown that GLP-1 infusion vasodilates conduit arteries and increases muscle microvascular perfusion in healthy (Chai et al., 2012) and insulin-resistant (Chai et al., 2014) rats, likely through a protein kinase A–NO-mediated pathway (Chai et al., 2012; Dong et al., 2013).”
BackgroundSelf-citationHabener, J. F., & Stanojevic, V. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.10.009 · Cited by 61
Li, Z., Ni, C.-L., Yao, Z., Chen, L.-M., & Niu, W.-Y. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.008 · Cited by 56
Salim, H. M., Fukuda, D., Higashikuni, Y., Tanaka, K., Hirata, Y., Yagi, S., Soeki, T., Shimabukuro, M., & Sata, M. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2015.08.011 · Cited by 56
The endothelium in diabetes: Its role in insulin access and diabetic complications
Kolka, C. M., & Bergman, R. N. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-012-9233-5 · Cited by 59
Glucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma
Nguyen, D.-V., Linderholm, A., Haczku, A., & Kenyon, N. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.06.012 · Cited by 57
“GLP-1 stimulation of endothelial NOS may also be an important beneficial effect in asthma (Chai et al., 2012; Ten Broeke et al., 2006).”
BackgroundIncretin actions beyond the pancreas: lessons from knockout mice
Yabe, D., & Seino, Y. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.013 · Cited by 57
“GLP-1 enhances nitric oxide production, leading to an increase of blood flow in the muscle [30].”
BackgroundFu, Z., Gong, L., Liu, J., Wu, J., Barrett, E. J., Aylor, K. W., & Liu, Z. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00555 · Cited by 50
“However, it did, similar to our prior findings (Chai et al., 2012, 2014; Dong et al., 2013), markedly increase both MBV and MBF in muscle (p < 0.05) without affecting MFV. Blood glucose and MAP remained stable during the study (Supplementary Figure 4).”
BackgroundMethodResultInfluentialSelf-citationZhao, L., Fu, Z., Wu, J., Aylor, K. W., Barrett, E. J., Cao, W., & Liu, Z. (2015) · The Journal of Physiology · doi:10.1113/jp270371 · Cited by 50
“…that increase muscle microvascular perfusion, such as exercise, insulin, glucagon-like peptide1, ranolazine and angiotensin II type 1 receptor blockade are all capable of increasing muscle insulin delivery and action (Vincent et al. 2004; Inyard et al. 2007; Chai et al. 2011, 2012; Fu et al. 2013).”
BackgroundSelf-citationWandrag, L., Siervo, M., Riley, H. L., Khosravi, M., Fernandez, B. O., Leckstrom, C. A., Martín, D., Mitchell, K., Levett, D. Z. H., Montgomery, H., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.05.004 · Cited by 57
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Chai, W., Fu, Z., Aylor, K. W., Barrett, E. J., & Liu, Z. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00205.2016 · Cited by 51
Self-citationSaxagliptin Restores Vascular Mitochondrial Exercise Response in the Goto-Kakizaki Rat
Keller, A. C., Knaub, L. A., Miller, M. W., Birdsey, N., Klemm, D. J., & Reusch, J. E. B. (2015) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000170 · Cited by 49
Muscle Insulin Resistance and the Inflamed Microvasculature: Fire from Within
Liu, J., & Liu, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030562 · Cited by 50
“The importance of muscle microcirculation in the regulation of insulin’s metabolic actions is further strengthened by many observations in both humans and laboratory animals that multiple factors with proven evidence to affect muscle insulin action and glucose metabolism are able to induce muscle microvasculature recr…”
BackgroundSelf-citationRanolazine recruits muscle microvasculature and enhances insulin action in rats
Fu, Z., Zhao, L., Chai, W., Dong, Z., Cao, W., & Liu, Z. (2013) · The Journal of Physiology · doi:10.1113/jphysiol.2013.257246 · Cited by 49
“…(Coggins et al. 2001), mixed meal (Keske et al. 2009), angiotensin II receptor blocker (Chai et al. 2010) and glucagon-like peptide 1 (GLP-1) (Chai et al. 2012), by way of increasing microvascular exchange surface area, leads to increased insulin delivery to and its action in skeletal muscle…”
BackgroundMethodInfluentialSelf-citationGPR120 agonism as a countermeasure against metabolic diseases
Cornall, L. M., Mathai, M. L., Hryciw, D. H., & McAinch, A. J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.021 · Cited by 50
The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis
Yajima, T., Yajima, K., Takahashi, H., & Yasuda, K. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.05.018 · Cited by 45
Sélley, E., Kun, S., Szijártó, I. A., Laczy, B., Kovács, T., Fülöp, F., Wittmann, I., & Molnár, G. A. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-69 · Cited by 49
Smits, M. M., Muskiet, M. H. A., Tonneijck, L., Kramer, M. H. H., Diamant, M., van Raalte, D. H., & Serné, E. H. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305447 · Cited by 44
The role of endothelial insulin signaling in the regulation of glucose metabolism
Kubota, T., Kubota, N., & Kadowaki, T. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9242-z · Cited by 51
Mechanisms of aerobic exercise impairment in diabetes: a narrative review
Wahl, M. P., Scalzo, R. L., Regensteiner, J. G., & Reusch, J. E. B. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00181 · Cited by 44
Ip, W., Shao, W., Chiang, Y.-T. A., & Jin, T. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00376.2013 · Cited by 43
The contributory role of vascular health in age‐related anabolic resistance
Banks, N. F., Rogers, E. M., Church, D. D., Ferrando, A. A., & Jenkins, N. D. M. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12898 · Cited by 44
Skrobucha, A., Pindlowski, P., Krajewska, N., Grabowski, M., & Jonik, S. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1446468 · Cited by 42
Love, K. M., Liu, J., Regensteiner, J. G., Reusch, J. E. B., & Liu, Z. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13045 · Cited by 40
Self-citationZhao, L., Chai, W., Fu, Z., Dong, Z., Aylor, K. W., Barrett, E. J., Cao, W., & Liu, Z. (2013) · Circulation Research · doi:10.1161/circresaha.111.300388 · Cited by 39
Self-citationSildenafil Increases Muscle Protein Synthesis and Reduces Muscle Fatigue
Sheffield‐Moore, M., Wiktorowicz, J. E., Soman, K. V., Danesi, C. P., Kinsky, M. P., Dillon, E. L., Randolph, K. M., Casperson, S. L., Gore, D. C., Horstman, A. M., et al. (2013) · Clinical and Translational Science · doi:10.1111/cts.12121 · Cited by 39
The Role of Gasotransmitters in Gut Peptide Actions
Verbeure, W., van Goor, H., Mori, H., van Beek, A. P., Tack, J. F., & van Dijk, P. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.720703 · Cited by 42
Thielen, S. C., Reusch, J. E. B., & Regensteiner, J. G. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1218692 · Cited by 41
The Impact of Antidiabetic Agents on Sarcopenia in Type 2 Diabetes: A Literature Review
Wu, C.-N., & Tien, K. (2020) · Journal of Diabetes Research · doi:10.1155/2020/9368583 · Cited by 40
Sarcopenia in chronic kidney disease: from bench to bedside
Kim, D. W., & Song, S. H. (2023) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2022.338 · Cited by 39
“Several classes of anti-diabetic agents have shown a positive effect on improving energy metabolism in muscles in vivo [68-72] and this review is focused on the most extensively investigated drug, metformin.”
HFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 37
Fu, Z., Zhao, L., Aylor, K. W., Carey, R. M., Barrett, E. J., & Liu, Z. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.03025 · Cited by 36
Self-citationDoes drug therapy reverse endothelial progenitor cell dysfunction in diabetes?
Desouza, C. V. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.04.007 · Cited by 36
Dietary Strategies to Improve Exercise Performance by Modulating the Gut Microbiota
Zhang, L., Li, H., Song, Z., Liu, Y., & Zhang, X. (2024) · Foods · doi:10.3390/foods13111680 · Cited by 35
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
“…increased muscle microvascular blood volume in the absence of changes in microvascular blood flow velocity or femoral blood flow, in association with increased plasma NO, muscle insulin clearance/uptake, hindlimb glucose extraction and muscle interstitial oxygen saturation (Chai et al., 2012).”
BackgroundInfluentialAhmadi, H. Z., & Hamann, S. (2025) · BMC Ophthalmology · doi:10.1186/s12886-025-03958-4 · Cited by 33
“Also, GLP-1 is known to induce nitric oxide mediated vasodilation, and rodent studies have demonstrated that GLP-1 infusion acutely increases microvascular perfusion [15].”
Glucagon‐like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle
Abdulla, H., Phillips, B. E., Wilkinson, D. J., Limb, M., Jandova, T., Bass, J. J., Rankin, D., Cegielski, J., Sayda, M., Crossland, H., et al. (2020) · Aging Cell · doi:10.1111/acel.13202 · Cited by 30
“…a s te d F e d F a s te d F e d 0 .0 0 .1 0 .2 0 .3 0 .4 0 .5–GLP-1 +GLP-1 (a) (b) (c) (d) (e) (g) (f) intra-arterially in contrast to studies in rats (Chai et al., 2012) and humans (Sjøberg, Holst, Rattigan, Richter, & Kiens, 2014; Subaran et al., 2014), where GLP-1 was infused intravenously.”
Kim, J. B., Lee, G. Y., Maeng, H. J., Kim, H., Bae, J. H., Kim, K. M., & Lim, S. K. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.781 · Cited by 33
“GLP-1 analogues improve insulin sensitivity in the liver and adipose tissue, reducing macrophage infiltration and inhibiting inflammation [4-7].”
BackgroundWang, N., Chai, W., Zhao, L., Tao, L., Cao, W., & Liu, Z. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00537.2012 · Cited by 33
“Muscle insulin uptake was determined in protocol 1 studies, using (125)I-insulin as tracer to track the uptake of native insulin, as described previously (8, 9, 22).”
BackgroundMethodSelf-citationIncretins and cardiovascular disease: to the heart of type 2 diabetes?
Solini, A., Tricò, D., & Del Prato, S. (2023) · Diabetologia · doi:10.1007/s00125-023-05973-w · Cited by 32
Abdulla, H., Phillips, B., Wilkinson, D., Gates, A., Limb, M., Jandova, T., Bass, J., Lewis, J., Williams, J., Smith, K., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac613 · Cited by 30
Yaribeygi, H., Farrokhi, F. R., Abdalla, M. A., Sathyapalan, T., Banach, M., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/6518221 · Cited by 31
Metadata
- Authors
- Chai, W., Dong, Z., Wang, N., Wang, W., Tao, L., Cao, W., & Liu, Z.
- Affiliations
- University of Virginia Health System (US)
- Shandong University (CN)
- Central South University (CN)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Liu, Zhenqi
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2012-03-14
- Volume
- 61
- Issue
- 4
- Pages
- 888-896
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3314347
- OpenAlex
- W2130375560
- Cited by
- 194
- References
- 47
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 9 · 2023: 9 · 2022: 11 · 2021: 17 · 2020: 13 · 2019: 9 · 2018: 17 · 2017: 8 · 2016: 13 · 2015: 15 · 2014: 24 · 2013: 23 · 2012: 6
- FWCI
- 17.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association (1-11-CR-30, 9-09-NOVO-11)
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL094722)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- glucagon-like peptide-1, nitric oxide, nitric oxide synthase, muscle microvasculature, muscle glucose uptake, microvascular blood flow, endothelial cells, insulin clearance, insulin resistance, vasodilation, glucose extraction
- MeSH terms
- Animals, Aorta, Cattle, Cells, Cultured, Drug Administration Schedule, Gene Expression Regulation, Glucose, Hormones, Insulin, Male, Nitric Oxide, Somatostatin, Rats, Sprague-Dawley, Cyclic AMP-Dependent Protein Kinases, Muscle, Skeletal, NG-Nitroarginine Methyl Ester, Endothelial Cells, Proto-Oncogene Proteins c-akt, Rats, Glucagon-Like Peptide 1, Nitric Oxide Synthase Type III, Microvessels
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.